Eledon Pharmaceuticals (NASDAQ:ELDN – Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.20, Zacks reports.
Eledon Pharmaceuticals Stock Performance
ELDN stock opened at $2.89 on Friday. The company has a market capitalization of $173.06 million, a P/E ratio of -1.44 and a beta of 0.08. Eledon Pharmaceuticals has a 52-week low of $2.30 and a 52-week high of $5.54. The business has a 50-day simple moving average of $3.19 and a two-hundred day simple moving average of $3.96.
Analysts Set New Price Targets
Separately, Guggenheim started coverage on Eledon Pharmaceuticals in a research note on Tuesday, January 28th. They set a “buy” rating and a $9.00 target price for the company.
About Eledon Pharmaceuticals
Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).
Read More
- Five stocks we like better than Eledon Pharmaceuticals
- What is the S&P 500 and How It is Distinct from Other Indexes
- Lockheed Martin: A Top Defense Pick in 2025
- Profitably Trade Stocks at 52-Week Highs
- If the U.S.-China Trade Reset Holds, These 3 Stocks Could Fly
- What is the Australian Securities Exchange (ASX)
- 3 Mid-Cap Stocks Turning Heads in AI, Automation, & Cybersecurity
Receive News & Ratings for Eledon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eledon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
